Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Conatus Pharmaceuticals Inc.

www.conatuspharma.com

Latest From Conatus Pharmaceuticals Inc.

Novartis’s NASH Chief: Our Strategy Is Combos With Tropifexor As ‘Backbone’

Novartis's broad but early-stage NASH pipeline will use FXR agonist tropifexor as its keystone for developing combination therapies with outside partners.

Research and Development Strategies Liver & Hepatic

Conatus Endures Another NASH Setback With Failure To Hit Fibrosis Endpoint

The pan-caspase inhibitor emricasan, partnered with Novartis, misses fibrosis-reduction endpoint in Phase IIb study, following the failure last December of a trial in portal hypertension.

Liver & Hepatic Clinical Trials

In NASH Race, Bad News For Conatus, Good News For Genfit In PBC

Conatus’ emricasan fails to meet the primary endpoint for portal hypertension in NASH patients with cirrhosis, but firm stresses promising subgroup data. Genfit hits Phase II primary endpoint in PBC with elafibranor, which is also in Phase III for NASH.

Liver & Hepatic Clinical Trials

Pfizer/Novartis Collaboration Brings Combined Strength To NASH Development

Combination therapy is expected to prevail in NASH. Pfizer and Novartis, while trailing smaller companies, are studying their candidates together in hopes of hitting on a winning combo for the multi-factorial disease.

Deals Research & Development
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Hepatic (Liver)
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Conatus Pharmaceuticals Inc.
  • Senior Management
  • Steven J Mento, PhD, Pres. & CEO
    Michelle L Vandertie, VP, Fin.
    Daniel L Ripley, VP, Bus. Dev. & Program Alliance Mgt.
    Alfred P Spada, PhD, EVP, R&D & CSO
  • Contact Info
  • Conatus Pharmaceuticals Inc.
    Phone: (858) 376-2600
    16745 West Bernardo Dr.
    Ste. 200
    San Diego, CA 92127
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register